FAQ · Cosmetic peptides

What is Argireline?

Argireline is the brand name for acetyl hexapeptide-8, a 6-amino-acid cosmetic peptide marketed as a topical line-reduction ingredient. The mechanism is to inhibit muscle contraction at the skin surface, analogous to (but vastly weaker than) botulinum toxin. Manufacturer-supported in-vitro and small-trial data suggest modest line-reduction effects with 5 to 10 percent topical use. Independent large RCT evidence is limited. Widely used in UK serums from The Ordinary, Skinceuticals, and many supplier-formulated brands.

The mechanism (in marketing terms)

Argireline is marketed as "topical Botox" because it acts at the SNARE protein complex that mediates neurotransmitter release at the neuromuscular junction. Manufacturer Lipotec\'s 2002 paper described in-vitro inhibition of this complex. Topical penetration of a 6-amino-acid peptide is limited, so the actual effect at the skin surface is modest compared to injected botulinum toxin which acts at the muscle directly.

The evidence base

• · Lipotec 2002 in-vitro work: established the SNARE-complex mechanism.
• · Lipotec-supported small trials: modest fine-line reduction at 5 to 10 percent topical concentrations over 30 days.
• · Independent large RCTs: limited.
• · Most consumer-facing studies are industry-funded with small sample sizes.

Realistic expectations

Topical peptides do not replicate injected botulinum toxin outcomes. Argireline at well-formulated concentration may produce modest fine-line softening over weeks of consistent use. It is not a substitute for muscle-paralysing aesthetic procedures. For dynamic wrinkle treatment (expression lines), the difference is significant.

Stacking

Argireline is pH-stable and stacks well with vitamin C, niacinamide, hyaluronic acid, and retinoids. Often combined with Matrixyl 3000 and snail mucin in multi-peptide formulations.

Related: Cosmetic peptide hub · Best UK serums.